These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25104843)

  • 1. Does "time is brain" also mean "time is clot"? Time dependency of tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.
    Tsivgoulis G; Alexandrov AV
    Stroke; 2014 Sep; 45(9):2555-6. PubMed ID: 25104843
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.
    Muchada M; Rodriguez-Luna D; Pagola J; Flores A; Sanjuan E; Meler P; Boned S; Alvarez-Sabin J; Ribo M; Molina CA; Rubiera M
    Stroke; 2014 Sep; 45(9):2734-8. PubMed ID: 25104845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute endovascular recanalization therapy in wake-up stroke.
    Kuruvilla A; Norris GM; Xavier AR
    J Neurol Sci; 2011 Jan; 300(1-2):148-50. PubMed ID: 21078516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safer thrombolysis for acute ischemic stroke: is early recanalization the key?
    Tanne D; Levine SR
    Neurology; 2008 Oct; 71(17):1300-1. PubMed ID: 18936422
    [No Abstract]   [Full Text] [Related]  

  • 5. Door-to-needle times in acute ischemic stroke: how low can we go?
    Smith EE; von Kummer R
    Neurology; 2012 Jul; 79(4):296-7. PubMed ID: 22622861
    [No Abstract]   [Full Text] [Related]  

  • 6. Intra-arterial thrombolysis: tissue plasminogen activator and other thrombolytic agents.
    Samaniego EA; Linfante I; Dabus G
    Tech Vasc Interv Radiol; 2012 Mar; 15(1):41-6. PubMed ID: 22464301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to letter regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
    Liao X; Wang Y; Wang Y
    Stroke; 2014 Dec; 45(12):e304. PubMed ID: 25342031
    [No Abstract]   [Full Text] [Related]  

  • 8. Sonothrombolysis for acute ischemic stroke: a systematic review of randomized controlled trials.
    Bor-Seng-Shu E; Nogueira Rde C; Figueiredo EG; Evaristo EF; Conforto AB; Teixeira MJ
    Neurosurg Focus; 2012 Jan; 32(1):E5. PubMed ID: 22208898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buying time for recanalization in acute stroke: arterial blood infusion beyond the occluding clot as a neuroprotective strategy.
    Ribó M; Molina C; Alvarez B; Dinia L; Alvarez-Sabin J; Matas M
    J Neuroimaging; 2009 Apr; 19(2):188-90. PubMed ID: 18800999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activation and thrombolysis for ischemic stroke.
    Medcalf RL; Davis SM
    Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter by Chao et al regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
    Chao AC; Po HL; Chan L
    Stroke; 2014 Dec; 45(12):e303. PubMed ID: 25342029
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
    Rubiera M; Alvarez-Sabín J; Ribo M; Montaner J; Santamarina E; Arenillas JF; Huertas R; Delgado P; Purroy F; Molina CA
    Stroke; 2005 Jul; 36(7):1452-6. PubMed ID: 15947260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenge of thrombolysis for acute ischaemic stroke: can we treat more patients?
    Hand PJ; Kwan J
    Intern Med J; 2006 Aug; 36(8):477-8. PubMed ID: 16866648
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke.
    Zhang B; Sun XJ; Ju CH
    Eur Neurol; 2011; 65(3):170-4. PubMed ID: 21372577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
    Schestatsky P; Picon PD
    Neurology; 2005 Dec; 65(11):1844; author reply 1844. PubMed ID: 16344546
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
    Coutts SB; Dubuc V; Mandzia J; Kenney C; Demchuk AM; Smith EE; Subramaniam S; Goyal M; Patil S; Menon BK; Barber PA; Dowlatshahi D; Field T; Asdaghi N; Camden MC; Hill MD;
    Stroke; 2015 Mar; 46(3):769-74. PubMed ID: 25677596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaking up is hard to do: tenecteplase in acute stroke.
    Schwamm LH
    Lancet Neurol; 2015 Apr; 14(4):343-5. PubMed ID: 25726503
    [No Abstract]   [Full Text] [Related]  

  • 18. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.
    Fan X; Yu Z; Liu J; Liu N; Hajjar KA; Furie KL; Lo EH; Wang X
    Stroke; 2010 Oct; 41(10 Suppl):S54-8. PubMed ID: 20876506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Acute Ischemic Stroke.
    Rabinstein AA
    Continuum (Minneap Minn); 2017 Feb; 23(1, Cerebrovascular Disease):62-81. PubMed ID: 28157744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.